qRT-PCR analysis indicated that bone tumors from mice treated with 1 μg/day and 5 μg/day halofuginone expressed significantly lower mRNA levels of RANKL and IL-11 than control groups (Fig. 3D, upper panel). Here, TNFSF11 is linked to bone neoplasm.